Mandy
Lv3
320 积分
2024-10-25 加入
-
Oral Muvalaplin for Lowering of Lipoprotein(a)
12天前
已关闭
-
Oral Muvalaplin for Lowering of Lipoprotein(a)
12天前
已完结
-
Naftopidil inhibits 5-hydroxytryptamine-induced platelet aggregation and 5-hydroxytryptamine uptake in platelets of healthy volunteers
1个月前
已完结
-
Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors
1个月前
已完结
-
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
1个月前
已完结
-
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
1个月前
已完结
-
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
1个月前
已完结
-
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
1个月前
已完结
-
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
1个月前
已完结
-
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
1个月前
已完结